• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » In Brief: Meds in the Fast Lane

In Brief: Meds in the Fast Lane

November 5, 2021
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.
In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials. Instead of the typical 2000 participants, many are approved through trials enrolling only 200.

For clinicians, this means the efficacy—and even more so the safety—of these expedited drugs cannot be fully trusted, particularly in the first few years of their release. Compared with traditional approvals, these drugs are 1.5 times more likely to see black box warnings added after their release (Mostaghim SR et al, BMJ 2017;358:j3837). In essence, our practices are the testing sites for the Phase III trials often skipped over in these approvals.

Both the fast-track and breakthrough designations require some initial evidence that the drug has the potential to fill an unmet need in a serious disorder. For that first step, the fast-track pathway allows animal studies, while the breakthrough pathway requires clinical data. In the end, both pathways require companies to provide clinical data to gain approval, but a third pathway, accelerated approval, allows biological markers to substitute for more direct clinical outcomes. For example, reduction in tumor size is a marker for cancer survival rates.

Aducanumab is the first neuropsychiatric drug to earn approval through the accelerated pathway, and the biomarker it depended on was amyloid plaques. However, it’s not clear that this is a meaningful marker of dementia, and that is just the beginning of the controversies surrounding this approval, which are detailed in this issue.

Biomarkers are unlikely to replace clinical outcomes in psychiatry anytime soon, but breakthrough and fast-track approvals are rapidly becoming the norm. Waiting in the wings are MDMA, psilocybin, an oral version of brexanolone (zuranolone), and combination pills for unipolar (bupropion-dextromethorphan) and bipolar depression (lurasidone-cycloserine). For patients with severe, refractory disorders, this is good news, and it’s for those patients that these meds should be reserved, at least until their safety is better established. Until then, we’ll need to keep our eyes wide open for unforeseen outcomes.
Table: Psychotropics With Expedited Approvals

Table: Psychotropics With Expedited Approvals

(Click to view full-sized PDF.)
General Psychiatry
KEYWORDS aducanumab cognition dementia fda neurology novel-drug
Aiken
Chris Aiken, MD.

Ask the Editor: Three Significant Food Interactions with ADHD Medications

More from this author
www.thecarlatreport.com
Issue Date: November 5, 2021
SUBSCRIBE NOW
Table Of Contents
How to Treat ADHD in Bipolar Disorder
In the News: Aducanumab (Aduhelm)
Viloxazine for ADHD
Listening to Depression: The Importance of Addressing Hearing Loss
Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia
Sleepwalking on Antipsychotics and Lithium
In Brief: Meds in the Fast Lane
How to Diagnose Bipolar Disorder
Nutritional Psychiatry in Practice
CME Post-Test - Bipolar Disorder, TCPR, November/December 2021
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.